Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.03 is 56% above its 3-year average of 0.02, near the low end of its 3-year range (0.00–0.22).
As of the fiscal period ended Tuesday, June 30, 2026. 1.99% above its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.03.
DEBT TO EQUITY RATIO
0.03
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
0.02
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+1.99%
CURRENT VS 3Y AVG
+55.78%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
-80.46%
vs the sector median at left
Beta Bionics, Inc.
Market Cap
$835.01M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
N/A
Market Cap
$843.53M
Debt to Equity Ratio
0.08
TTM Avg
0.18
3Y Avg
0.20
5Y Avg
0.16
Market Cap
$817.92M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$865.29M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$791.01M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.03
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $835.01M | 0.03 | 0.02 | 0.02 | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $843.53M | 0.08 | 0.18 | 0.20 | 0.16 |
| Alumis Inc. (ALMS)vs › | $825.62M | 0.08 | 0.12 | 0.12 | 0.12 |
| Apnimed, Inc. (APMD)vs › | $818.83M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $817.92M | 0.00 | 0.01 | 0.01 | 0.01 |
| Ardelyx, Inc. (ARDX)vs › | $809.02M | 1.72 | 1.08 | 0.72 | 0.64 |
| InMode Ltd. (INMD)vs › | $808.81M | 0.01 | 0.01 | 0.01 | 0.01 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $865.29M | 0.00 | 0.03 | 0.03 | 0.03 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $791.01M | 0.03 | 0.02 | 0.02 | 0.03 |
| AdaptHealth Corp. (AHCO)vs › | $793.88M | 1.50 | 1.31 | 1.32 | 1.45 |
Debt/Equity
0.03
Current Ratio
8.88
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.03 |
| 2026-03-31 | 0.03 |
| 2025-12-31 | 0.03 |
| 2025-09-30 | 0.03 |
| 2025-06-30 | 0.02 |
| 2025-03-31 | 0.02 |
| 2024-12-31 | 0.10 |
| 2024-09-30 | 0.22 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.07 |
| 2023-09-30 | 0.00 |
